Related Experiment Video

Updated: Jul 1, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.6K

Oxaliplatin desensitization for ovarian cancer in pregnancy: A case report

Kaitlin Nicholson1,2, Lily Jia2,3, Margaret Rowe4

  • 1Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA, United States.

Gynecologic Oncology Reports
|March 4, 2024
PubMed

Keywords:
DesensitizationHypersensitivity reactionOvarian cancerPlatinum chemotherapy

More Related Videos

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines11:50

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

13.5K
Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing05:35

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Published on: September 15, 2023

1.5K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
200